Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer

Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer. This clearance allows the company to initiate a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing, and preliminary antitumor activity, supported by preclinical pharmacology, toxicology, and biomarker data.

Triple-negative breast cancer is an aggressive subtype of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 overexpression, making it particularly challenging to treat with conventional therapies. The approval of Telomir-Zn's IND marks a significant milestone for Telomir Pharmaceuticals as it advances its lead candidate toward clinical development. The company's focus on small-molecule therapeutics that target fundamental epigenetic and metabolic mechanisms could offer a new approach for patients with limited treatment options.

Telomir-Zn, also known as Telomir-1, has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. These mechanisms are implicated not only in cancer but also in aging and degenerative diseases, highlighting the broad potential of the company's platform.

The FDA's clearance underscores the robustness of the preclinical data package submitted by Telomir Pharmaceuticals. The Phase 1/2 trial will enroll patients with advanced or metastatic triple-negative breast cancer and will be conducted at multiple sites. The primary endpoints will focus on safety and tolerability, with secondary endpoints including pharmacokinetics, pharmacodynamics, and preliminary efficacy signals.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has shown promise in preclinical studies. For more information, visit the company's newsroom at https://ibn.fm/TELO.

The full press release is available at https://ibn.fm/p4e9J. This development is important as it represents a potential new therapeutic avenue for triple-negative breast cancer, a disease with high unmet medical need. The initiation of clinical trials will provide critical data on the safety and efficacy of Telomir-Zn, which could ultimately lead to improved outcomes for patients.